Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on July 24, 2013. The registrant is a Delaware corporation headquartered in San Diego, California. The report discloses a specific corporate event under Item 8.01 (Other Events).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a specific event and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the issuance of U.S. Patent 8,486,626 on July 24, 2013. The patent is titled "Methods of detecting cell-free miRNA in urine and blood." This represents an expansion of the company's intellectual property portfolio.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or specific risk factors. The press release associated with the patent issuance is furnished as Exhibit 99.1 but is explicitly stated not to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the exact scope and claims of U.S. Patent 8,486,626 via the USPTO database.
- Review the full text of the press release (Exhibit 99.1) for details on the commercial application of the new patent.
- Confirm the company's current financial status through its most recent 10-Q or 10-K filing, as this 8-K contains no financial data.
- Check for any subsequent filings regarding the commercialization or licensing of the patented technology.